Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis

Annals of Surgical Oncology

Volumn 21, Issue 9, 2014, Pages 3023-3028

  Ceelen, Wim ^a   Van Nieuwenhove, Yves ^a   Putte, Dirk Vande ^a   Pattyn, Piet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; ASPERGILLOSIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; COLORECTAL PERITONEAL CARCINOMATOSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; FEMALE; FOLLOW UP; HEMOPERITONEUM; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOPERFUSION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT; PERITONEUM CANCER; PROSPECTIVE STUDY; SURGICAL MORTALITY; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; COLORECTAL NEOPLASMS; CYTOREDUCTIVE SURGERY; HYPERTHERMIC THERAPY; MIDDLE AGED; MORTALITY; PATHOLOGY; PERITONEAL NEOPLASMS; PROGNOSIS; REGIONAL PERFUSION; SECONDARY; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MITOMYCIN; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84906228367     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3713-7     Document Type: Article

References (24)

1. Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci. 2010;14:249-58.
2. Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum - applying current evidence to clinical practice. Cancer Treat Rev. 2012;38:397-406.
3. Klaver YLB, Simkens LHJ, Lemmens V, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617-23.
4. Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012;13:E362-9.
5. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-43. (Pubitemid 46606227)
6. Ceelen WP. Current management of peritoneal carcinomatosis from colorectal cancer. Minerva Chir. 2013;68:77-86.
7. Ceelen W, De Somer F, Van Nieuwenhove Y, Vande Putte D, Pattyn P. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin. Eur J Surg Oncol. In press.
8. Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, Pattyn P. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol. 2008;15:535-41. (Pubitemid 351643030)
9. Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JWW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128:2717-25.
10. Konigsrainer I, Horvath P, Struller F, Forkl V, Konigsrainer A, Beckert S. Risk factors for recurrence following complete cytoreductive surgery and HIPEC in colorectal cancer - derived peritoneal surface malignancies. Langenbecks Arch Surg. 2013;398:745-9.
11. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63-8.
12. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284-92. (Pubitemid 41103684)
13. Cavaliere F, De Simone M, Virzi S, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011;37:148-54.
14. Passot G, Vaudoyer D, Cotte E, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012;256:125-29.
15. Klaver YLB, de Hingh I, Boot H, Verwaal VJ. Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy. J Surg Oncol. 2011;103:431-4.
16. Moghaddam SM, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2012;31:143-62.
17. Retsky MW, Hrushesky WJM, Gukas ID. Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer. BMC Cancer. 2009;9.
18. Nasti G, Piccirillo MC, Izzo F, et al. Neoadjuvant FOLFIRI plus bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer. 2013;108:1566-70.
19. Eveno C, Passot G, Goere D, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. In press.
20. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008;26:5254-60.
21. Chereau E, Lambaudie E, Houvenaeghel G. Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer. Int J Gynecol Cancer. 2013;23:1326-30.
22. van der Pool AE, Marsman HA, Verheij J, et al. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. J Surg Oncol. 2012;106:892-7.
23. Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA. A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res. 2013;179: E133-39.
24. Glockzin G, von Breitenbuch P, Schlitt HJ, Piso P. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. J Surg Oncol. 2013;107:574-8.